CA2030237A1 - Methode de traitement de l'alcoolisme par inhibition du besoin de boire par administration percutanee d'un antagoniste des opiaces et dispositif permettant l'administration dudit antagoniste - Google Patents

Methode de traitement de l'alcoolisme par inhibition du besoin de boire par administration percutanee d'un antagoniste des opiaces et dispositif permettant l'administration dudit antagoniste

Info

Publication number
CA2030237A1
CA2030237A1 CA2030237A CA2030237A CA2030237A1 CA 2030237 A1 CA2030237 A1 CA 2030237A1 CA 2030237 A CA2030237 A CA 2030237A CA 2030237 A CA2030237 A CA 2030237A CA 2030237 A1 CA2030237 A1 CA 2030237A1
Authority
CA
Canada
Prior art keywords
extinguishing
alcohol
opiate antagonist
transdermally administered
treating alcoholism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2030237A
Other languages
English (en)
Other versions
CA2030237C (fr
Inventor
John David Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contral Clinics Oy
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2030237A1 publication Critical patent/CA2030237A1/fr
Application granted granted Critical
Publication of CA2030237C publication Critical patent/CA2030237C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002030237A 1989-11-20 1990-11-19 Methode de traitement de l'alcoolisme par inhibition du besoin de boire par administration percutanee d'un antagoniste des opiaces et dispositif permettant l'administration dudit antagoniste Expired - Lifetime CA2030237C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US439,050 1989-11-20
US07/439,050 US5096715A (en) 1989-11-20 1989-11-20 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Publications (2)

Publication Number Publication Date
CA2030237A1 true CA2030237A1 (fr) 1991-05-21
CA2030237C CA2030237C (fr) 1997-12-30

Family

ID=23743078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002030237A Expired - Lifetime CA2030237C (fr) 1989-11-20 1990-11-19 Methode de traitement de l'alcoolisme par inhibition du besoin de boire par administration percutanee d'un antagoniste des opiaces et dispositif permettant l'administration dudit antagoniste

Country Status (10)

Country Link
US (1) US5096715A (fr)
EP (1) EP0429039B1 (fr)
AT (1) ATE119393T1 (fr)
AU (1) AU639042B2 (fr)
CA (1) CA2030237C (fr)
DE (1) DE69017596T2 (fr)
DK (1) DK0429039T3 (fr)
ES (1) ES2074513T3 (fr)
FI (1) FI905718L (fr)
NZ (2) NZ247173A (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
DE4223004A1 (de) * 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041987B1 (fr) 1997-12-22 2006-04-19 Euro-Celtique S.A. Formulation pharmaceutique pour administration orale comprenant en combinaison un agoniste des récepteurs opiacés et la naltrexone
EP1041988A4 (fr) 1997-12-22 2002-03-13 Euro Celtique Sa Procede prevenant l'abus des doses orales d'opioides
ATE399565T1 (de) 1998-07-07 2008-07-15 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht- irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
WO2001040269A2 (fr) * 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (fr) 2000-02-08 2013-03-20 Euro-Celtique S.A. Compositions orales inviolables comprenant des agonistes opioïdes
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US20060121103A1 (en) * 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
EP1387673B1 (fr) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
RU2004107501A (ru) * 2001-08-14 2005-02-20 Байотай Терапис Корпорейшн (Fi) Способ лечения алкоголизма или злоупотребления алкоголем
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
CN1703200B (zh) * 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (fr) * 2004-09-23 2006-03-30 Alexander Michalow Methodes permettant de reguler les systemes de neurotransmetteurs en induisant des contre-adaptations
US7910599B2 (en) 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
EP1702558A1 (fr) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
SI2719378T1 (sl) * 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
EP2152315B1 (fr) 2007-05-25 2016-01-06 Indivior UK Limited Formulations d'administration prolongée de composés de rispéridone
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2259780A2 (fr) 2008-02-28 2010-12-15 Syntropharma Limited Composition pharmaceutique comprenant de la naltrexone
EP2317991B1 (fr) * 2008-07-07 2017-05-03 Euro-Celtique S.A. Utilisation d'antagonistes opioïdes pour le traitement d'une rétention urinaire
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2011064769A1 (fr) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procédés et compositions pharmaceutiques pour le traitement des bouffées de chaleur
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11607026B2 (en) * 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
CN111447927A (zh) * 2017-12-08 2020-07-24 帝国制药美国公司 纳洛酮经皮给药装置及其使用方法
US12364692B2 (en) 2020-02-14 2025-07-22 Teikoku Pharma Usa, Inc. Topical naloxone compositions and methods for using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837881A (en) * 1952-12-13 1958-06-10 Lawrence A Schneider Encapsulated product and method and apparatus for making same
US3249109A (en) * 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US4629539A (en) * 1982-07-08 1986-12-16 Tdk Corporation Metal layer patterning method
AU8952282A (en) * 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
DE3545926A1 (de) * 1985-12-23 1987-07-02 Allan Gerhard Fruehauf Tuch oder dgl. mit darin integrierten, einen wirkstoff enthaltenden kapseln
ES2042527T3 (es) * 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
EP0282156B1 (fr) * 1987-03-09 1991-04-17 Alza Corporation Composition pour la prévention d'une allergie de contact par co-administration d'un corticostéroide avec un médicament sensibilisant
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Also Published As

Publication number Publication date
DK0429039T3 (da) 1995-03-27
US5096715A (en) 1992-03-17
AU639042B2 (en) 1993-07-15
EP0429039B1 (fr) 1995-03-08
AU6665090A (en) 1991-05-23
CA2030237C (fr) 1997-12-30
DE69017596T2 (de) 1995-07-06
ES2074513T3 (es) 1995-09-16
FI905718A7 (fi) 1991-05-21
FI905718L (fi) 1991-05-21
DE69017596D1 (de) 1995-04-13
EP0429039A2 (fr) 1991-05-29
ATE119393T1 (de) 1995-03-15
NZ247173A (en) 1997-07-27
EP0429039A3 (en) 1991-10-16
NZ236104A (en) 1993-04-28
FI905718A0 (fi) 1990-11-20

Similar Documents

Publication Publication Date Title
CA2030237A1 (fr) Methode de traitement de l'alcoolisme par inhibition du besoin de boire par administration percutanee d'un antagoniste des opiaces et dispositif permettant l'administration dudit antagoniste
IE890343L (en) Ultrasonic contrast agents, process for their preparation and their use as diagnostic and therapeutic agents
JPS55162716A (en) Medicinal composition
CA2164689A1 (fr) Antagonistes du recepteur nk-1 et antagonistes du recepteur 5ht3 pour le traitement des vomissements
IE893625L (en) Pharmaceutical ion exchange resin composition
EP0178140A3 (fr) Systèmes thérapeutiques transdermiques pour l'administration de nalozone, naltrexone et nalbuphine
CA2213339A1 (fr) Procede de traitement de la depletion de l'adenosine
PL326497A1 (en) Pharmaceutic preparation for trancutaneous administration of active substances
GR61591B (en) Therapeutic system and method for administering clonidine transdermally
CA2135639A1 (fr) Preparation a liberation controlee contenant un sel de morphine
EP0251717A3 (fr) Protéine chimiquement modifiée, activant les ílots
CA2075904A1 (fr) Methode de traitement du syndrome pre-menstruel
CA2024188A1 (fr) Methode de traitement de l'ejaculation prematuree a l'aide de la sertraline
AU7185294A (en) Effervescent system with an alkali- and/or metal-sensitive pharmaceutical active substance and process for producing the same
GB1390772A (en) Oral narcotic composition
IE882391L (en) Pad printing process
CA2118512A1 (fr) Agents utilises dans le traitement des toxicomanies
MY130107A (en) Piperidylmethyl-substituted chroman derivatives
HUT50765A (en) Process for producing compounds with analgesic action on central nervous system and pharmaceutical compositions comprising such compounds
CA2171124A1 (fr) Pellicule/bande radioactives et methode de preparation
CA2107587A1 (fr) Suppression des niveaux du thromboxane par l'administration percutanee d'aspirine
JPS5233667A (en) Process for preparation of hydrogenated 1-oxo-isoindoline derivatives
PH22596A (en) Bicyclo (3.2.2.) octane carboxylic acid derivatives, process for their preparation and therapeutic application thereof
CA2048894A1 (fr) Methode de traitement de la mastocytose
JPS5310693A (en) Preparation of nylon copolymer

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry